Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000060553 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ankylosing spondylitis: From pathogenesis to therapy.
Int Immunopharmacol
January 2025
State Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Life Sciences, Nanjing University, 163 Xianlin Avenue, Nanjing 210023, Jiangsu, China. Electronic address:
Ankylosing spondylitis (AS) is an autoimmune rheumatic disease that primarily affects the axial joints, with its etiology complex and still not fully understood. The unknown pathogenesis of AS limits the development of treatment strategies, so keeping up-to-date with the current research on AS can help in searching for potential therapeutic targets. In addition to the classic HLA-B27 genetic susceptibility and Th17-related inflammatory signals, increasing research is focusing on the influence of autoantigen-centered autoimmune responses and bone stromal cells on the onset of AS.
View Article and Find Full Text PDFBrentuximab-Induced Acute Interstitial Nephritis: A Case Report.
Can J Kidney Health Dis
November 2024
Division of Nephrology, Department of Medicine, University of Saskatchewan, Saskatoon, Canada.
Brentuximab vedotin is a combination monoclonal antibody to anti-CD30 conjugated to the anti-tubulin agent monomethyl auristatin E. It is approved for the treatment of mycosis fungoides, Hodgkin's lymphoma, and systemic anaplastic large cell lymphoma. Brentuximab has been associated with a number of potential adverse reactions; however, reports of renal complications are rare.
View Article and Find Full Text PDFDecoupling immunomodulatory properties from lipid binding in the α-pore-forming toxin Sticholysin II.
Int J Biol Macromol
November 2024
Center for Protein Studies/Department of Biochemistry, Faculty of Biology, University of Havana, Havana 10400, Cuba; NanoCancer, Center of Molecular Immunology (CIM), Havana 11600, Cuba. Electronic address:
Sticholysin II (StII), a pore-forming toxin from the marine anemone Stichodactyla helianthus, enhances an antigen-specific cytotoxic T lymphocyte (CTL) response when co-encapsulated in liposomes with a model antigen. This capacity does not depend exclusively on its pore-forming activity and is partially supported by its ability to activate Toll-like receptor 4 (TLR4) in dendritic cells, presumably by interacting with this receptor or by triggering signaling cascades upon binding to lipid membrane. In order to investigate whether the lipid binding capacity of StII is required for immunomodulation, we designed a mutant in which the aromatic amino acids from the interfacial binding site Trp110, Tyr111 and Trp114 were substituted by Ala.
View Article and Find Full Text PDFExercise, autoimmune diseases and T-regulatory cells.
J Autoimmun
December 2024
Zabludowicz Centre for Autoimmune Diseases, Sheba Medical Centre, Tel-Hashomer, Israel; Reichman University, Herzelia, Israel. Electronic address:
Diverse forms of physical activities contribute to improvement of autoimmune diseases and may prevent disease burst. T regulatory cells (Tregs) maintain tolerance in autoimmune condition. Physical activity is one of the key factors causing enhancement of Tregs number and functions, keeping homeostatic state by its secrotome.
View Article and Find Full Text PDFImmunopeptidomics in the cancer immunotherapy era.
Explor Target Antitumor Ther
July 2024
Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.
Cancer is the primary cause of death worldwide, and conventional treatments are painful, complicated, and have negative effects on healthy cells. However, cancer immunotherapy has emerged as a promising alternative. Principle of cancer immunotherapy is the re-activation of T-cell to combat the tumor that presents the peptide antigen on major histocompatibility complex (MHC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!